BIODEFENSE BRIEFING: Say Anthrax, or Who Got What in NIH FY03 Grants for Biodefense and Category A Pathogens | GenomeWeb

NEW YORK, Oct. 24 (GenomeWeb News) - Anthrax seemed to be the magic word that opened up the purse of the NIH in fiscal year 2003, with vaccines, immunity, and smallpox running close behind, an analysis of extramural NIH funding for biodefense and Category A pathogens indicates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.